Thromb Haemost 1993; 69(01): 041-044
DOI: 10.1055/s-0038-1651545
Original Article
Coagulation
Schattauer GmbH Stuttgart

Effect of Heparin on Thrombin Inhibition in the Microcirculation

S Nydahl
The Departments of Surgery and Experimental Surgery, Karolinska Hospital, Stockholm, Sweden
,
S Frebelius
The Departments of Surgery and Experimental Surgery, Karolinska Hospital, Stockholm, Sweden
,
J Swedenborg
The Departments of Surgery and Experimental Surgery, Karolinska Hospital, Stockholm, Sweden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 10. April 1992

Accepted after revision 07. September 1992

Publikationsdatum:
04. Juli 2018 (online)

Summary

Disappearance of thrombin enzymatic activity was measured during recirculation through the microvasculature in a rat Langendorff heart preparation. This resulted in a 50% loss of thrombin from the recirculating solution. No increased loss of thrombin could be demonstrated if a mixture of antithrombin III and thrombin was recirculated, compared to thrombin alone. If, however, a heparin/thrombin mixture was recirculated, a 90% loss of thrombin could be demonstrated. Pretreating the microvasculature with large amounts of heparin resulted in recovery of antithrombin III in the recirculated heparin solution. At a subsequent recirculation with a heparin/thrombin mixture the loss of thrombin was decreased to the control level, as seen when recirculation with thrombin alone was performed. It is concluded that disappearance of thrombin enzymatic activity from a solution when recirculated through the microcirculation can be considerably increased if recirculated together with heparin, which probably reacts with endogenous antithrombin III on the vessel wall. The disappearance of thrombin in the absence of heparin was, however, unaffected by antithrombin III. The latter finding is compatible with the hypothesis that, in the microcirculation, antithrombin III/glycosaminoglycans play only a minor role for inhibition of thrombin coagulant activity and that thrombin binds mainly to thrombomodulin.

 
  • References

  • 1 Marcum JA, Atha DH, Fritze LMS, Nawroth P, Stern D, Rosenberg RD. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparin sulfate proteoglycan. J Biol Chem 1986; 261: 7507-7517
  • 2 Esmon CT, Esmon NI. Protein C activation. Semin Thromb Hemostas 1984; 10: 122-130
  • 3 Busch C, Owen WG. Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest 1982; 69: 726-729
  • 4 Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984; 74: 341-350
  • 5 Frebelius S, Nydahl S, Swedenborg J. Coagulant and noncoagulant thrombin enzymatic activity on the endothelium. Blood Coagulation Fibrinolysis 1990; 1: 285-292
  • 6 Nydahl S, Frebelius S, Swedenborg J. Thrombin inactivation and the effects of antithrombin and heparin in a recirculating Langendorff preparation. Thromb Res 1992; 65: 365-376
  • 7 MacIntosh S, Owen WG. Regulation of the clearance and inhibition of intravascular thrombin. Thrombosis Scientific and Clinical Perspectives. London: Sanofi Foundation for Thrombosis Research. Bull No. 1 1987
  • 8 Langendorff O. Untersuchungen am überlebenden Säugetierherzen. Pflügers Arch 1895; 61: 291
  • 9 Abildgaard U, Lie M, Ödegård OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and chromozym TH). Thromb Res 1977; 11: 549-553
  • 10 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
  • 11 Kirk RE. Experimental Design. Procedures for the Behavioral Sciences. Brooks/Cole Publishing Company; Montery: 1982
  • 12 Busch C, Concilla PA, Debault LE, Goldsmith JG, Owen WG. Methods in laboratory investigation: use of endothelium cultured on microcarriers as a model for the microcirculation. Lab Invest 1981; 47: 498-504
  • 13 Zwaginga JJ, de Boer HC, IJsseldijk MJW, Kerkhof A, Müller-Berghaus G, Gruhlichhenn J, Sixma JJ, de Groot PG. Thrombogenicity of vascular cells. Comparison between endothelial cells isolated from different sources and smooth muscle cells and fibroblasts. Arteriosclerosis 1990; 10: 437-448
  • 14 Dupuy E, Bikfalvi A, Rendu F, Levy Toledano S, Tobelem G. Thrombin mitogenic responses and protein phosphorylation are different in cultured human endothelial cells derived from large and microvessels. Exp Cell Res 1989; 185: 363-372
  • 15 Speiser W, Anders E, Preissner KT, Wagner O, Müller-Berghaus G. Differences in coagulant and fibrinolytic activities of cultured human endothelial cells derived from omental tissue microvessels and umbilical veins. Blood 1987; 69: 964-967
  • 16 Pasche B, Elgue G, Olsson P, Riesenfeld J, Rasmuson A. Binding of antithrombin to immobilized heparin under varying flow conditions. Art Organs 1991; 15 (06) 481-491
  • 17 Lollar P, Macintosh S, Owen WG. Reaction of antithrombin III with thrombin bound to the vascular endothelium. Analysis in a recirculating perfused rabbit heart preparation. J Biol Chem 1984; 259: 4335-4338
  • 18 Delvos U, Meusel P, Preissner KT, Müller-Berghaus G. Formation of activated protein C and inactivation of cell-bound thrombin by antithrombin III at the surface of cultured vascular endothelial cells – a comparative study of two anticoagulant mechanisms. Thromb Haemostas 1987; 57 (01) 87-91
  • 19 Hatton MWC, Moar SL. Comparison of the effects of heparin and hirudin on thrombin binding to the normal and the de-endothelialized rabbit aorta in vitro. Thromb Haemostas 1991; 66 (02) 208-212
  • 20 Bourin M-C, Öhlin A-K, Lane DA, Stenflo J, Lindahl U. Relationship between anticoagulant activities and polyanionic properties of rabbit thrombomodulin. J Biol Chem 1988; 263 (17) 8044-8052